Therapy with MEK inhibitor U0126 produces only a transient inhibition of tumor glycolytic activity but does not inhibit tumor growth, which is most likely due to continuing IGF2-induced signaling from IGF1R through the PI3K-AKT-mTOR pathway. This evidence concerns the gene MAP2K7 and neoplasm.